公开(公告)号：US12048729B2

公开(公告)日：2024-07-30

申请号：US16780851

申请日：2020-02-03

Applicant: Rachel Sarah Levine

Inventor： Rachel Sarah Levine

IPC: A61K38/06 ,  A61K8/14 ,  A61K9/06 ,  A61K9/127 ,  A61K9/70 ,  A61K36/185 ,  A61K36/28 ,  A61K36/58 ,  A61K38/44 ,  A61K47/10 ,  A61K47/14 ,  A61K47/24 ,  A61K47/36 ,  A61K47/44

CPC classification number: A61K38/063 ,  A61K9/06 ,  A61K9/127 ,  A61K9/7007 ,  A61K9/7038 ,  A61K36/185 ,  A61K36/28 ,  A61K36/58 ,  A61K38/44 ,  A61K47/10 ,  A61K47/14 ,  A61K47/24 ,  A61K47/36 ,  A61K47/44

Abstract: A transdermal formulation which can be applied to the skin, body, face using a combination of glutathione, in the presence of a wide range of active components while increasing permeation of active antioxidant agents. A therapeutically effective amount creates in the patient (i) regulation of sleep, (ii) increased energy during awake periods, (iii) improved concentration during awake periods, (iv) reduction of facial wrinkles, and (v) reduction of joint and muscular pain with increases by at least 10 percent of the ability of skin to retain moisture and totally absorb the glutathione without requiring injection or oral supplementation of the glutathione.

公开(公告)号：US12023369B2

公开(公告)日：2024-07-02

申请号：US17552499

申请日：2021-12-16

Applicant: GELITA AG

Inventor： Steffen Oesser ,  Stephan Hausmanns ,  Hans-Ulrich Frech

IPC: A61K38/00 ,  A23L2/00 ,  A23L33/00 ,  A23L33/18 ,  A61K8/65 ,  A61K9/00 ,  A61K31/122 ,  A61K31/4745 ,  A61K35/36 ,  A61K36/77 ,  A61K36/82 ,  A61K38/01 ,  A61K38/06 ,  A61K38/39 ,  A61K38/44 ,  A61P3/02 ,  A61Q19/06

CPC classification number: A61K38/39 ,  A23L2/00 ,  A23L33/18 ,  A23L33/30 ,  A61K8/65 ,  A61K9/0053 ,  A61K31/122 ,  A61K31/4745 ,  A61K35/36 ,  A61K36/77 ,  A61K36/82 ,  A61K38/011 ,  A61K38/014 ,  A61K38/063 ,  A61K38/446 ,  A61P3/02 ,  A61Q19/06 ,  A61K2800/92 ,  A61K38/063 ,  A61K2300/00 ,  A61K38/446 ,  A61K2300/00 ,  A61K38/014 ,  A61K2300/00 ,  A61K38/011 ,  A61K2300/00 ,  A61K36/82 ,  A61K2300/00 ,  A61K36/77 ,  A61K2300/00 ,  A61K35/36 ,  A61K2300/00 ,  A61K31/122 ,  A61K2300/00 ,  A61K31/4745 ,  A61K2300/00

Abstract: The present invention relates to the use of collagen hydrolysate for improving endurance performance by increasing mitochondrial activity. Further, the invention relates to the use of collagen hydrolysate for stimulating lipid catabolism, and in particular for reducing body weight, by increasing mitochondrial activity.

公开(公告)号：US20240139277A1

公开(公告)日：2024-05-02

申请号：US17999356

申请日：2021-05-19

Applicant: TOHOKU UNIVERSITY ,  Bio-Xcelerator, Inc.

Inventor： Takaaki AKAIKE ,  Satoshi TAKAGI ,  Hisatoshi SUGIURA ,  Kenji INABA

IPC: A61K38/06 ,  A61K31/198 ,  A61P31/14

CPC classification number: A61K38/063 ,  A61K31/198 ,  A61P31/14

Abstract: There is provided a drug which exhibits preventive and therapeutic effects on virus infectious diseases by inhibiting virus-derived protease on the basis of various physiological activity actions of an active sulfur compound(s) which exists in living organisms.

公开(公告)号：US20240009265A1

公开(公告)日：2024-01-11

申请号：US17922487

申请日：2021-04-30

Applicant: Blue Sky Innovation, LLC

Inventor： Danny C. Purser ,  Stephen N. Pitcher

IPC: A61K38/06 ,  A61K9/00 ,  A61P17/02 ,  A61K31/545 ,  A61K9/127

CPC classification number: A61K38/063 ,  A61K9/0014 ,  A61P17/02 ,  A61K31/545 ,  A61K9/127

Abstract: The present disclosure is drawn to a method of treating a subject having a condition responsive to treatment with reduced glutathione (rGSH), comprising: administering a therapeutically effective amount of a substantially α-D-glucopyranoside-free stabilized rGSH composition to the subject.

公开(公告)号：US11841369B2

公开(公告)日：2023-12-12

申请号：US16767985

申请日：2018-11-28

Applicant: CELL2IN, INC.

Inventor： Heun Soo Kang ,  Hye Mi Kim ,  Ji Eun Song ,  Gwang Mo Yang ,  Ji Woong Shin ,  Hye Won Kang ,  Yong Hwan Kim ,  Myung Jin Kim

IPC: G01N33/68 ,  G01N21/64 ,  G01N33/50 ,  A61K38/06

CPC classification number: G01N33/68 ,  A61K38/063 ,  G01N21/6428 ,  G01N33/5005 ,  G01N33/5044 ,  G01N33/5076 ,  G01N33/6815 ,  G01N33/6893 ,  G01N2021/6439 ,  G01N2800/7009

Abstract: The present invention relates to a method of improving the quality of therapeutic cells by real-time glutathione monitoring.

公开(公告)号：US11766407B2

公开(公告)日：2023-09-26

申请号：US17403966

申请日：2021-08-17

Applicant: FoodScience Corporation

Inventor： Adam Killpartrick ,  Mingruo Guo ,  Alyssa Humphrey Kemp

IPC: A61K9/50 ,  A61K31/404 ,  A61K38/06 ,  A61K31/122

CPC classification number: A61K9/5052 ,  A61K9/5089 ,  A61K31/122 ,  A61K31/404 ,  A61K38/063

Abstract: A process is provided for encapsulating glutathione (GSH), 3,3′-diindolylmethane (DIM), coenzyme-Q10 (CoQ10), and other hydrophobic antioxidant compounds by using whey proteins which may be polymerized in a particular manner. Further, compositions comprising polymerized whey protein (PWP) encapsulated glutathione, polymerized whey protein (PWP) encapsulated CoQ10, and polymerized whey protein (PWP) encapsulated DIM are provided.

公开(公告)号：US20230263833A1

公开(公告)日：2023-08-24

申请号：US18310100

申请日：2023-05-01

Applicant: Cerus Corporation

Inventor： Anna ERICKSON ,  Mary Ann SCHOTT ,  Blake WARBINGTON

IPC: A61K35/18 ,  A61K31/198 ,  A61K31/473 ,  A61K35/16 ,  A61K38/06

CPC classification number: A61K35/18 ,  A61K31/198 ,  A61K31/473 ,  A61K35/16 ,  A61K38/063

Abstract: The present disclosure relates to compositions and methods for treating red blood cells compositions with a pathogen-inactivation compound and for preparing pathogen-inactivated red blood cells.

公开(公告)号：US20230181675A1

公开(公告)日：2023-06-15

申请号：US17916504

申请日：2021-04-01

Applicant: ARECOR LIMITED

Inventor： David GERRING ,  Sarah HOWELL ,  Jan JEZEK ,  Leon ZAKRZEWSKI

IPC: A61K38/06 ,  A61K47/02 ,  A61K47/12 ,  A61K9/00 ,  A61K31/455 ,  A61K45/06 ,  A61K31/557

CPC classification number: A61K38/063 ,  A61K9/0019 ,  A61K31/455 ,  A61K31/557 ,  A61K45/06 ,  A61K47/02 ,  A61K47/12

Abstract: There is provided, inter alia, an aqueous liquid pharmaceutical formulation comprising (i) a fast acting insulin analogue; (ii) ionic zinc; and (ill) citrate, said formulation being substantially free of a zinc binding species having a logK with respect to zinc ion binding of greater than 12.3 at 25° C.; for use in the treatment of a human subject suffering from diabetes mellitus by administration by subcutaneous injection or subcutaneous infusion at or close to a meal-time wherein the administration of 0.3 U/kg of the formulation leads to one or more specified pharmacokinetic and/or pharmacodynamic parameters.

公开(公告)号：US20230172900A1

公开(公告)日：2023-06-08

申请号：US17912687

申请日：2021-02-04

Applicant: Wellington Silva

Inventor： Wellington Silva

IPC: A61K31/353 ,  A61K31/07 ,  A61K38/06 ,  A61K31/05 ,  A61K31/122 ,  A61K36/889 ,  A61K31/381

CPC classification number: A61K31/353 ,  A61K31/05 ,  A61K31/07 ,  A61K31/122 ,  A61K31/381 ,  A61K36/889 ,  A61K38/063

Abstract: The present invention patent application relates essentially to a supplement, the function of which is to enhance immunity, prevent various diseases and assist in therapeutic treatments of various diseases, said supplement being composed of: 100 mg of lipoic acid, 1 mg of astaxanthin, 10 mg of glutathione, 5 mg of resveratrol, 5 mg of lycopene, 50 mg of epigallocatechin, 300 mg of curcumin, 400 mg of quercetin, 10 mg of coenzyme Q1 and 100 mg of dry açaí extract; formulated with the intention of combining substances that serve functions of assisting in the treatment of various diseases, such as: lipoic acid, which helps in the prevention of liver damage from intoxication, and can be used as a coadjuvant for the treatment of liver cirrhosis due to alcoholism and a coadjuvant for the treatment of diabetes and cataracts.

公开(公告)号：US20190209499A1

公开(公告)日：2019-07-11

申请号：US16334256

申请日：2017-09-26

Applicant: GENEHEAL BIOTECHNOLOGY CO., LTD.

Inventor： Wuguang PAN ,  Wei ZHU

IPC: A61K31/155 ,  A61P35/00 ,  A61K38/05 ,  A61K38/06 ,  A61K31/661 ,  A61K31/132 ,  A61K31/198 ,  A61K31/7076 ,  A61K31/675 ,  A61K31/415 ,  A61K31/4402 ,  A61K31/513

CPC classification number: A61K31/155 ,  A61K31/132 ,  A61K31/197 ,  A61K31/198 ,  A61K31/33 ,  A61K31/397 ,  A61K31/40 ,  A61K31/415 ,  A61K31/4188 ,  A61K31/43 ,  A61K31/435 ,  A61K31/4402 ,  A61K31/513 ,  A61K31/661 ,  A61K31/675 ,  A61K31/7072 ,  A61K31/7076 ,  A61K31/708 ,  A61K38/05 ,  A61K38/06 ,  A61K38/063 ,  A61K38/07 ,  A61P3/00 ,  A61P25/00 ,  A61P25/08 ,  A61P25/14 ,  A61P35/00 ,  A61P43/00 ,  C07D213/00 ,  C07D403/00 ,  C07D487/00 ,  C07D513/00 ,  C07H19/20 ,  C07H21/00

Abstract: Provided are compounds reducing SAICAR accumulation, and applications. On the basis of existing protein structure data and small molecule structure data, calculations and analysis are performed using software to screen and obtain compounds capable of effectively interfering with PAICS activity, reducing SAICAR synthesis, and ultimately reducing SAICAR accumulation, in order to achieve the goal of treating or improving ADSL deficiency. A better effect in the treatment or improvement of ADSL deficiency is expected from the joint use of at least two of the described compounds.